Somewhat Positive Media Coverage Somewhat Unlikely to Impact EXACT Sciences (EXAS) Stock Price
Media headlines about EXACT Sciences (NASDAQ:EXAS) have trended somewhat positive on Thursday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EXACT Sciences earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.393818624023 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Optimistic Trending Companies: Exact Sciences Corporation (EXAS), Energy Transfer Partners, LP (ETP) – Market Movers (financialqz.com)
- EXACT Sciences Corp. – Value Analysis (NASDAQ:EXAS) : December 13, 2017 (finance.yahoo.com)
- It may surprise you:- Exact Sciences Corporation (NASDAQ:EXAS) – Market Breaking Point (press release) (journalfinance.net)
- Hot Tickers: Argos Therapeutics, Inc. (ARGS), Exact Sciences Corporation (EXAS) – Market Movers (financialqz.com)
- EXACT Sciences Corp. breached its 50 day moving average in a Bearish Manner : EXAS-US : December 12, 2017 (finance.yahoo.com)
EXACT Sciences (EXAS) traded down $0.66 during trading on Thursday, hitting $51.22. The stock had a trading volume of 1,052,300 shares, compared to its average volume of 2,459,999. EXACT Sciences has a twelve month low of $13.05 and a twelve month high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.
Several equities research analysts have recently weighed in on EXAS shares. Bank of America increased their price objective on EXACT Sciences from $58.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, November 29th. BidaskClub raised EXACT Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Canaccord Genuity reissued a “buy” rating and issued a $45.00 price objective on shares of EXACT Sciences in a report on Thursday, September 7th. Leerink Swann reissued an “outperform” rating and issued a $67.00 price objective (up from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. Finally, Robert W. Baird downgraded EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price objective for the company. in a report on Monday, November 13th. Nine investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. EXACT Sciences presently has an average rating of “Hold” and a consensus price target of $50.58.
In other news, CEO Kevin T. Conroy sold 137,805 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the completion of the sale, the chief executive officer now owns 967,867 shares in the company, valued at $57,239,654.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP D Scott Coward sold 29,115 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the sale, the senior vice president now owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The disclosure for this sale can be found here. Insiders have sold 595,396 shares of company stock valued at $32,953,769 in the last 90 days. Company insiders own 4.00% of the company’s stock.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Stock Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related stocks with our FREE daily email newsletter.